IMPEDE-VTE
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk-7–3
- Intermediate Risk4–7
- High Risk8–19
The IMPEDE-VTE calculates predicting risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. Key inputs include immunomodulatory drug. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.
Clinical Indication
The IMPEDE-VTE is indicated for bedside clinical practice to support Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: C-statistic 0.66-0.74 across validation studies demonstrates good discrimination.
Score = (IMiD use: 4 pts) + (BMI ≥25: 1 pt) + (Pelvic/hip/femur fracture: 4 pts) + (ESA use: 1 pt) + (Doxorubicin: 3 pts) + (Dexamethasone low: 2 pts, high: 4 pts) + (Asian/PI ethnicity: -3 pts) + (VTE history: 5 pts) + (Tunneled line/CVC: 2 pts) + (Therapeutic anticoagulation: -4 pts) + (Prophylactic anticoagulation: -3 pts)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| immunomodulatory_drug | string | Yes | Use of immunomodulatory drugs (lenalidomide, thalidomide, pomalidomide). IMiDs significantly increase VTE risk in multiple myeloma patients through multiple mechanisms including increased platelet aggregation and endothelial dysfunction |
| bmi_25_or_greater | string | Yes | Body mass index ≥25 kg/m². Overweight and obesity are established risk factors for VTE through multiple mechanisms including increased inflammatory markers, decreased mobility, and compression of venous return |
| pelvic_hip_femur_fracture | string | Yes | Pathologic fracture of pelvis, hip, or femur. Bone lesions and fractures are common in multiple myeloma and significantly increase VTE risk through immobilization and local inflammatory processes |
| erythropoiesis_stimulating_agent | string | Yes | Use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin or darbepoetin. ESAs increase VTE risk by raising hematocrit and blood viscosity, and may increase platelet reactivity |
| doxorubicin_use | string | Yes | Use of doxorubicin as part of multiple myeloma treatment regimen. Doxorubicin increases VTE risk through endothelial damage and increased coagulation factor activity |
| dexamethasone_use | string | Yes | Dexamethasone dosing level. High-dose dexamethasone (≥160mg/month or ≥40mg/week) significantly increases VTE risk more than low-dose regimens through effects on coagulation factors and platelet function |
| asian_pacific_islander | string | Yes | Asian or Pacific Islander ethnicity. This population has lower baseline VTE risk compared to other ethnicities, possibly due to genetic factors affecting coagulation cascade and fibrinolysis |
| history_of_vte | string | Yes | History of venous thromboembolism (deep vein thrombosis or pulmonary embolism) prior to multiple myeloma diagnosis. Previous VTE is the strongest predictor of recurrent thrombotic events |
| tunneled_line_cvc | string | Yes | Presence of tunneled central venous catheter or central line. Central venous catheters increase VTE risk through direct endothelial injury, flow disruption, and serving as nidus for thrombus formation |
| therapeutic_anticoagulation | string | Yes | Current therapeutic anticoagulation with warfarin or low molecular weight heparin (LMWH). Therapeutic anticoagulation significantly reduces VTE risk when used appropriately |
| prophylactic_anticoagulation | string | Yes | Current prophylactic anticoagulation with low molecular weight heparin (LMWH) or aspirin. Prophylactic measures provide moderate VTE risk reduction in high-risk patients |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| -7–3 | Low Risk | Score ≤3 points |
| 4–7 | Intermediate Risk | Score 4-7 points |
| 8–19 | High Risk | Score ≥8 points |
Evidence-Based References (EBM)
- Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019 Nov;94(11):1176-1184. doi: 10.1002/ajh.25603.DOI: 10.1002/ajh.25603
- Sanfilippo KM, Luo S, Wang TF, et al. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol. 2021 Jun;193(5):1005-1015. doi: 10.1111/bjh.17396.DOI: 10.1111/bjh.17396
- Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019 Jul 1;17(7):840-847. doi: 10.6004/jnccn.2018.7273.DOI: 10.6004/jnccn.2018.7273
- National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2023). https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf